MediPharm Labs (TSX:LABS) Interest Expense : C$-0.66 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. MediPharm Labs's interest expense for the three months ended in Sep. 2024 was C$ -0.24 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.66 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. MediPharm Labs's Operating Income for the three months ended in Sep. 2024 was C$ -2.71 Mil. MediPharm Labs's Interest Expense for the three months ended in Sep. 2024 was C$ -0.24 Mil. MediPharm Labs did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MediPharm Labs Interest Expense Historical Data

The historical data trend for MediPharm Labs's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs Interest Expense Chart

MediPharm Labs Annual Data

Trend

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.44

-7.88

-10.51

-0.03

-0.37

MediPharm Labs Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-0.15	-0.10	-0.11	-0.21	-0.24

MediPharm Labs Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.66 Mil.

MediPharm Labs (TSX:LABS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MediPharm Labs's Interest Expense for the three months ended in Sep. 2024 was C$-0.24 Mil. Its Operating Income for the three months ended in Sep. 2024 was C$-2.71 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was C$0.04 Mil.

MediPharm Labs's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

MediPharm Labs did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

MediPharm Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (TSX:LABS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

MEDIF:USA MLZ:Germany

Address

151 John Street, Barrie, ON, CAN, L4N 2L1

Website

https://www.medipharmlabs.com

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

Executives

Keith Strachan	Director
Gregory Edison Hunter	Senior Officer
David Pidduck	Director, Senior Officer
Bryan Howcroft	Director, Senior Officer
Patrick Mccutcheon	Director
Warren Everitt	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Etf Managers Trust	10% Security Holder
Christopher David Taves	Director
Sybil Taylor	Senior Officer
Braden Fenske	Senior Officer
David John Mayers	Senior Officer